CoChat

Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study

The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index.

Abstract

Background/objective There are limited real-world studies assessing semaglutide weight loss and associated comorbidity and metabolic outcomes over periods ≥ 6 months. We aim to assess weight loss, metabolic, and cardiovascular outcomes of 12 months of semaglutide.Subject/methods We conducted a multicentered retrospective cohort study on semaglutide use. We included patients with a body-mass index (BMI) ≥ 27 kg/m 2 who were prescribed weekly semaglutide subcutaneous injections. We excluded patients with bariatric surgeries, taking other anti-obesity medications, and with active malignancy or pregnancy. A total of 1023 patients had semaglutide prescription for obesity.Intervention/methods We assessed weight loss outcomes of subcutaneous semaglutide for 12 months. The primary endpoint was total body weight loss percentage (TBWL%) at 12 months. Secondary endpoints included proportion of patients achieving ≥5%, ≥10%, ≥15%, and ≥20% weight loss, and improvements in metabolic, cardiovascular, and comorbidities after 12 months of follow-up.Results We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m 2) in the analysis. Patients achieved a TBWL of 13.4 (8.0)% at 12 months (p < 0.001 from baseline). Patients without T2DM achieved a TBWL of 16.9 (6.9)% compared to 9.9 (8.4)% in patients without T2DM at 12 months on the higher doses of semaglutide (p < 0.001 from baseline). In this cohort, 81% achieved ≥5%, 64% achieved ≥10%, 41% achieved ≥15%, and 22% achieved ≥20% TBWL at 12 months. Patients with overweight or obesity experienced significant improvements in metabolic, lipid profile, blood pressure, liver function tests, and cardiovascular disease risk outcomes.Conclusions Semaglutide demonstrated notable improvement in obesity, metabolic, and cardiovascular disease risk outcomes in a clinical setting.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41366-023-01456-5

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 15 references

Research works printed but not linked: 1

  1. Tchang BG, Aras M, Kumar RB, Aronne LJ. Pharmacologic treatment of overweight and obesity in adults. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279038/. 2015.

Cited by

See all 35

Metadata

Authors
Ghusn, W., Fansa, S., Anazco, D., Tama, E., Nicolalde, B., Gala, K., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feres, F., Hurtado, M. D., & Acosta, A.
Affiliations
Mayo Clinic (US)
Corresponding author
Acosta, Andres
Venue
International Journal of Obesity
Published
2024-02-01
Volume
48
Issue
5
Pages
662-667
ISSN
  • 0307-0565 (ISSN-L)
  • 1476-5497
OpenAlex
W4391445680
Cited by
35
References
16
Citations by year
2026: 12 · 2025: 14 · 2024: 9
FWCI
9.94
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • International Journal of Obesity (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK114460)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
semaglutide, weight loss, obesity, type 2 diabetes, cardiovascular risk, metabolic outcomes, lipid profile, blood pressure, liver function tests, anti-obesity drugs, GLP-1 receptor agonists
MeSH terms
Heart Disease Risk Factors, Semaglutide, Adult, Cardiovascular Diseases, Glucagon-Like Peptides, Female, Humans, Male, Middle Aged, Obesity, Retrospective Studies, Weight Loss, Treatment Outcome, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study. https://app.cochat.ai/papers/10.1038/s41366-023-01456-5
The paper
Ghusn, W., Fansa, S., Anazco, D., Tama, E., Nicolalde, B., Gala, K., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feres, F., Hurtado, M. D., & Acosta, A. (2024). Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study. International Journal of Obesity. https://doi.org/10.1038/s41366-023-01456-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.